Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension

Journal of Human Hypertension volume 22, pages 338–345 (2008)Cite this article

Abstract

The aim of the study was to investigate the effect of therapy by perindopril or telmisartan on endothelial/platelet function and on coagulation/fibrinolysis in 20 and 16 hypertensive patients, respectively. The measurements were carried out before and after 1 month of therapy. Both systolic blood pressure and diastolic blood pressure were reduced (P<0.001) or normalized due to each therapy. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, plasma β-thromboglobulin (βTG), platelet factor 4 (PF4), soluble P-selectin (sPsel) and soluble glycoprotein V (sGpV) as indicators of in vivo platelet activation, plasminogen activator inhibitor type 1 (PAI-1) antigen and tissue type plasminogen activator (tPA) antigen as markers of fibrinolytic activity, soluble endothelial protein C receptor (sEPCR) as a new marker of hypercoagulation and fibrinogen level as a known risk factor for vascular changes were investigated. A decrease of plasma vWF, sPsel, sGpV, PAI-1 and tPA antigen level (P<0.05, respectively) after 1 month of therapy by perindopril was observed. On the other hand, a decrease of plasma sEPCR and fibrinogen level (P<0.05, respectively) after 1 month of therapy by telmisartan was found. We failed to find changes of plasma TM, βTG and PF4 due to any therapy investigated. The additional beneficial ‘antithrombotic’ effects of the renin–angiotensin system targeting agents (vasculoprotective, anti-platelet and profibrinolytic effects of perindopril and anticoagulant/rheological effects of telmisartan) may be important in terms of the favourable role of antihypertensive drugs in cardiovascular morbidity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Seci LA, Zingaro L, Catena C, Casaccio D, De Marchi S . Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000; 36: 978–985.

    Article  Google Scholar 

  2. Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY . Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44: 415–422.

    Article  Google Scholar 

  3. Spencer CGC, Martin SC, Felmden DC, Blann AD, Beevers GD, Lip GYH . Relationship of homocysteine to markers of platelet and endothelial activation in ‘high risk’ hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol 2004; 94: 293–300.

    Article  Google Scholar 

  4. Lip GYH, Blann AD, Edmunds E, Beevers DG . Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension. Blood Coagul Fibrinolysis 2002; 13: 35–41.

    Article  CAS  Google Scholar 

  5. Sakata K, Pawlak R, Urano T, Takada A . Effects of a long-term pharmacological interruption of the renin–angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb 2002; 32: 67–75.

    Article  CAS  Google Scholar 

  6. Dielis AWJH, Smid M, Spronk HMH, Houben AJHM, Hamulyák K, Kroon AA et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost 2007; 5: 1509–1515.

    Article  CAS  Google Scholar 

  7. Curran MP, McCormack PL, Simpson D, Perindopril. A review of its use in patients with or at risk of developing coronary artery disease. Drugs 2003; 66: 1–21.

    Google Scholar 

  8. Battershill AJ, Scott LJ, Telmisartan. A review of its use in the management of hypertension. Drugs 2006; 66: 51–83.

    Article  CAS  Google Scholar 

  9. Remko M . Acidity, lipophilicity, solubility, absorption, and polar surface area of some ACE inhibitors. Chem Pap 2007; 61: 133–141.

    Article  CAS  Google Scholar 

  10. Zhuo JL, Mendelsohn FAO, Ohishi M . Perindopril alters vascular angiotensin-converting enzyme, AT1 receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39 (Part 2): 634–638.

    Article  CAS  PubMed  Google Scholar 

  11. Blann AD, Naqvi T, Waite M, McCollum CN . von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107–111.

    CAS  PubMed  Google Scholar 

  12. Remkova A, Kratochvilova H . Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 2002; 16: 549–555.

    Article  CAS  PubMed  Google Scholar 

  13. Lee KW, Blann AD, Lip GY . High pulse pressure and nondipping circadian blood pressure in patients with coronary artery disease: relationship to thrombogenesis and endothelial damage/dysfunction. Am J Hypertens 2005; 18: 104–115.

    Article  PubMed  Google Scholar 

  14. Vischer UM . von Willebrand factor, endothelial dysfunction and cardiovascular disease. J Thromb Haemost 2006; 4: 1186–1193.

    Article  CAS  PubMed  Google Scholar 

  15. Ceconi C, Fox KM, Remme WJ, Simoons ML, Bertrand M, Parrinello G, et al., on behalf of the EUROPA and the PERTINENT investigators. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–246.

    Article  CAS  PubMed  Google Scholar 

  16. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–1286.

    Article  CAS  PubMed  Google Scholar 

  17. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A . Effects of antihypertensive drugs on endothelial dysfunction—clinical implications. Drugs 2002; 62: 265–284.

    Article  CAS  PubMed  Google Scholar 

  18. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y et al. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol 2003; 41: 1373–1379.

    Article  CAS  PubMed  Google Scholar 

  19. Ferrari R, Arbustini E, Blann A, Cokkinos D, Kluft C, de Maat MPM et al. PERTINENT–PERindopril–thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drug Ther 2003; 17: 83–91.

    Article  CAS  Google Scholar 

  20. The European trial on reduction of cardiac events with perindopril in stable artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet 2003; 362: 782–788.

    Article  Google Scholar 

  21. Okrucká A, Pecháň J, Kratochvíl'ová H . Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension. Platelets 1998; 9: 63–67.

    Article  Google Scholar 

  22. Remkova A, Kovacova E, Prikazska M, Kratochvilova H . Thrombomodulin as a marker of endothelium damage in some clinical conditions. Eur J Int Med 2000; 11: 79–84.

    Article  CAS  Google Scholar 

  23. Blann AD, Nadar SK, Lip GYH . The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166–2179.

    Article  CAS  Google Scholar 

  24. Riondino S, Pignatelli P, Pulcinelli FM, Lenti L, Di Veroli C, Marigliano V et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc 1999; 47: 943–947.

    Article  CAS  Google Scholar 

  25. Nadar SK, Blann AD, Lip GY . Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med 2004; 36: 552–557.

    Article  CAS  Google Scholar 

  26. Nadar SK, Blann AD, Lip GY . Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The west Birmingham stroke project. Thromb Haemost 2004; 92: 1342–1348.

    Article  CAS  Google Scholar 

  27. Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis—the influence of aspirin and cigarette smoking. Thromb Haemost 2001; 86: 777–783.

    Article  CAS  Google Scholar 

  28. Wolff V, Aleil B, Giroud M, Lorenzini JL, Meyer N, Wiesel ML et al. Soluble platelet glycoprotein V is a marker of thrombosis in patients with ischemic stroke. Stroke 2005; 36: e17–e19.

    CAS  Google Scholar 

  29. Atalar E, Haznedaroglu IC, Kilic H, Ozer N, Coskun S, Ozturk E et al. Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking. Platelets 2005; 16: 329–333.

    Article  CAS  Google Scholar 

  30. Aleil B, Meyer N, Wolff V, Kientz D, Wiesel ML, Gachet C et al. Plasma glycoprotein V levels in the general population: normal distribution, associated parameters and implications for clinical studies. Thromb Haemost 2006; 96: 505–511.

    Article  CAS  Google Scholar 

  31. Kishi Y, Ohta S, Kasuya N, Sakita S, Ashikaga T, Isobe M . Perindopril augments ecto-ATP diphosphohydrolase activity and enhances endothelial anti-platelet function in human umbilical vein endothelial cells. J Hypertens 2003; 21: 1347–1353.

    Article  CAS  Google Scholar 

  32. Montón M, Jiménez A, Núňez A, López-Blaya A, Farré J, Gómez J et al. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation. J Cardiovasc Pharmacol 2000; 35: 906–913.

    Article  Google Scholar 

  33. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I et al. Association of blood pressure with fibrinolytic potential in the Framingham Offspring study. Circulation 2000; 101: 264–269.

    Article  CAS  PubMed  Google Scholar 

  34. Tomiyama H, Kimura Y, Mitsuhashi H, Kinouchi T, Yoshida H, Kushiro T et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension 1998; 31 (Part 2): 321–327.

    Article  CAS  PubMed  Google Scholar 

  35. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T . Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes. Diabetes Care 2005; 28: 2211–2216.

    Article  CAS  PubMed  Google Scholar 

  36. Koh KK, Chung WJ, Ahn JY, Han SH, Kang WC, Seo YH et al. Angiotensin II type receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo controlled study. Atherosclerosis 2004; 177: 155–160.

    Article  CAS  PubMed  Google Scholar 

  37. Fogari R, Zoppi A, Malamani G, Marasi G, Pesce RM, Banderali A et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women in hypertension. Curr Ther Res Clin Exp 2001; 62: 68–78.

    Article  CAS  Google Scholar 

  38. Erlinger TP, Conlin PR, Macko RF, Bohannon AD, Miller III ER, Moore TJ et al. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. J Hum Hypertens 2002; 16: 391–397.

    Article  CAS  PubMed  Google Scholar 

  39. Li-Saw-Hee FL, Beevers DG, Lip GYH . Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241–246.

    Article  CAS  PubMed  Google Scholar 

  40. Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T et al. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 2007; 25: 1643–1649.

    Article  CAS  Google Scholar 

  41. Erdem Y, Usalan C, Haznedaroglu IC, Altun B, Arici M, Yasavul U et al. Effects of angiotensin-converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12 (Part 1): 1071–1076.

    Article  CAS  Google Scholar 

  42. Fogari R, Mugellini A, Zoppi, Corradi L, Preti P, Lazzari P et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15 (Part 1): 316–320.

    Article  CAS  Google Scholar 

  43. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S . A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is candidate risk factor for thrombosis. Blood 2004; 103: 1311–1318.

    Article  CAS  Google Scholar 

  44. Nagel JM, Tietz AB, Gõke B, Parhofer KG . The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149–1154.

    Article  CAS  Google Scholar 

  45. Remková A, Kratochvíl'ová H . Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolysis 2000; 7: 641–644.

    Article  Google Scholar 

  46. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783–788.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Mrs V Tokarova, Mrs H Mackovychova and Mrs V Volanska for their technical assistance. This research was supported by grants from the Slovak Ministry of Education (VEGA grant nos. 1/2290/05 and 1/4301/07).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, School of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic

    A Remková, H Kratochvíl'ová & J Ďurina

Authors
  1. A Remková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kratochvíl'ová
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Ďurina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Remková.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remková, A., Kratochvíl'ová, H. & Ďurina, J. Impact of the therapy by renin–angiotensin system targeting antihypertensive agents perindopril versus telmisartan on prothrombotic state in essential hypertension. J Hum Hypertens 22, 338–345 (2008). https://doi.org/10.1038/sj.jhh.1002328

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002328

Keywords

This article is cited by

Search

Advanced search

Quick links